解放军医学杂志2012，Vol.37Issue(1)：54-58,5.
尼妥珠单抗联合伊立替康二线治疗晚期结直肠癌的回顾性分析
A retrospective analysis of nimotuzumab plus irinotecan as second-line treatment in advanced colorectal cancer
周军 1沈琳 1高静 1张小田 1李健1
作者信息
- 1. 100142北京 北京大学肿瘤医院暨北京市肿瘤防治研究所、恶性肿瘤发病机制及转化研究教育部重点实验室消化肿瘤内科
- 折叠
摘要
Abstract
Objective To investigate tentatively the safety and therapeutic efficacy of nimotuzumab in the process of treating colorectal cancer. Methods The clinical data of 11 patients suffering from advanced colorectal cancer and receiving nimotuzumab plus irinotecan treatment from July 2009 to January 2011 were analyzed retrospectively. Dosage regimen: 400mg of nimotzumab was given weekly, and 180mg/m2 of irinotecan was given every two weeks. The therapeutic efficacy and untoward effects were determined based on the evaluation criteria of therapeutic effectiveness (RECIST) 1.0 and the evaluation criteria of common untoward effect (CTCAE) 3.0, respectively. Results Among the 11 patients, 1 was in partial remission and 4 were stable. The target effective rate was 9.1% (1/11), with the control rate of the disease being 45.5% (5/11). The progress free survival rate (PFS) was 37-519 (medium value 55)d. The medium survival rats was not yet obtained. The untoward effect was mild. Two cases of skin rashes were observed, and it might be related to nimotuzumab, and there was one case of infusion reaction. Untoward effects of over grade 3 included one case of asthenia, four cases of inhibition of bone marrow function, and one case of vomiting. Conclusions The administration of nimotuzumab at 400mg weekly plus irinotecan is safe. Further study is necessary to assess the best dosage in order to improve the therapeutic effectiveness.关键词
尼妥珠单抗/结直肠肿瘤/伊立替康/受体,表皮生长因子Key words
nimotuzumab/ colorectal neoplasms/ irinotecan/ receptor, epidermal growth factor分类
医药卫生引用本文复制引用
周军,沈琳,高静,张小田,李健..尼妥珠单抗联合伊立替康二线治疗晚期结直肠癌的回顾性分析[J].解放军医学杂志,2012,37(1):54-58,5.
